the Circle. · CGTI 2027 · Berlin
Uwe Gottschalk · Conference Chair · Operating Partner, Keensight Capital
What delivers.
What sustains.
Who reaches the patient.
The pathway that holds. The infrastructure between vector and patient is being built.
Less noise. More signal.
01
Every cell and gene therapy leader carries the same weight. How does clinical proof become patient access at scale? The answer is decided at release, along the vein to vein chain and at the payer's table.
02
The white space is the room that holds the conversation differently. Closed-door. By invitation. End-user led. No expo hall. No vendor pitch. A circle for the leaders closing the gap between science and the patient who cannot wait.
03
the Conversation. CGTI is that room. Senior cell and gene therapy leadership convened around the work that compounds. Release at speed. Identity from vein to vein. Access at scale.
04
Who attends. Senior faculty drawn from the leaders who own the programme, sign the batch record and carry the accountability.
Cell & Gene Therapy Innovation 2027
For decision makers from small biotech to global pharma, accountable for what reaches the patient.
The gap.
Cell and gene therapy moves faster than the infrastructure designed to deliver it. Accenture's February 2026 study traces 64% of drug launch delays to chemistry, manufacturing and controls. In cell and gene therapy that file is the vector, the release and the vein to vein chain. The leaders accountable for it have not had the room they need.
The Conversation.
CGTI convenes the leaders building the infrastructure that closes that gap: vector supply and release, the vein to vein chain, reimbursement and patient access. The corridor where CGT ambition becomes clinical supply, or breaks. The Conversation is where the leaders who carry the accountability meet before the patient does.
The decision.
What delivers. What sustains. Who reaches the patient. Three questions the room must hold before the process locks. For the leaders who own the programme, sign the batch record and are accountable for the gap no one has formally closed.
Uwe Gottschalk
Conference Chair · Operating Partner, Keensight Capital
The room.
Cell & Gene Therapy Innovation · Berlin · 2027
"
Not a conference. A room where the work compounds.
Uwe Gottschalk · Conference Chair · CGTI 2027
the circle. forum · in the room
cgti.ai · the years before · by GBX Circle
On stage at CGTI 2025 · cgti.ai
the room · GBX Circle
the conversation · CGTI
in the room · CGTI
the room assembled · CGTIorganisations in the Circle
By invitation. By relevance. By room.
Up to
150
senior leaders
Ratio
80/20
end-user · partner
Format
Two
days
closed-door
By invitation. By relevance. By room.
The leaders who own the programme, sign the batch record and carry the accountability for what reaches the patient.
Pharma · Biotech · CDMO · Academic Medical
CGTI 2027 · Berlin.
Who attends.
Key partners · confirmed
the circle. · access
The prospectus is not public. Shared directly with the organisations that belong. Who attends.
"Not a conference. A room where the work compounds."
Uwe Gottschalk · Conference Chair · CGTI 2027
The room. The conversations. The decisions.
A note on privacy.
This site uses essential cookies to function. We optionally use analytics to understand how the site is used. Nothing is shared. Nothing is sold.